Radioligand Therapies – Opportunities and Challenges for Switzerland and Globally
Panel discussion summary
to be added soon
Date, time and room information
May 6, 15:00-15:45, Marriott 1+2
Moderation
| Name | Position | Institution |
|---|---|---|
| Philippe Legenne | CMO | Molecular Partners |
Panelists
| Name | Position | Institution |
|---|---|---|
| Melpomeni Fani | Head of Radiopharmaceutical Chemistry | University Hospital Basel |
| Sibylle Jennings | Global Regulatory Team Lead | Radiosensitive Cancers, Novartis |
| Emanuele Ostuni | CEO | ARTBIO |
| Arnaud Lesegretain | CEO | Orano Med |
Molecular Partners AG
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of a new class of custom-built protein drugs known as DARPin therapeutics.
The Company has programs in pre-clinical and clinical development and partnerships with leading pharmaceutical companies to bring innovative solutions to cancer patients.
Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA.
Host and event manager:
Logistics and marketing partner:
